Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:21 - 80
Updated:9/9/2018
Start Date:April 2016
End Date:December 2021
Contact:Amy Walters
Email:amy.walters@microvention.com
Phone:714.247.8000

Use our guide to learn which trials are right for you!

Pivotal Study of the MicroVention, Inc. Carotid Artery Stent System Used in Conjunction With the Nanoparasol® Embolic Protection System for the Treatment of Carotid Artery Stenosis in Patients at Elevated Risk for Adverse Events From Carotid Endarterectomy.(CONFIDENCE Trial)

A prospective, multicenter, single-arm, open label clinical study to evaluate the safety and
effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with
the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in
patients with elevated risk for adverse events following carotid endarterectomy.

A total of 295 patients will be enrolled for this study. All potential patients being
considered for the study should have been diagnosed with significant carotid artery stenosis
and be considered a high perioperative risk for carotid endarterectomy.

Patients will be evaluated through screening, pre-procedure, index procedure, post-procedure.
Follow-up visits will be completed at 30 days, 6 months, and 12, 24, and 36 months
post-procedure.

Inclusion Criteria:

1. Patient is between >21 and ≤80 years of age.

2. Patient is willing and capable of complying with all study protocol requirements,
including specified follow-up period and can be contacted by telephone.

3. Patient or authorized legal representative is willing to provide written informed
consent prior to enrollment in study.

4. Patient should have been diagnosed with carotid artery stenosis and be considered a
high operative risk for carotid endarterectomy.

5. Patient is either:

- Symptomatic with carotid stenosis ≥50% as determined by angiography using NASCET
methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid
lesion; TIA or non-disabling stroke within 180 days of the procedure within the
hemisphere supplied by the target vessel; or

- Asymptomatic with carotid stenosis ≥80% as determined by angiography using NASCET
methodology.

6. Patient has a target lesion located at the carotid bifurcation and/or proximal ICA.

7. Patient has a single de novo or restenotic (post CEA) target lesion or severe tandem
lesions close enough that can be covered by a single Roadsaver™ stent.

8. Patients having a vessel with reference diameters between 3.0 mm and 9.0 mm at the
target lesion.

High Risk Inclusion Criteria

For inclusion in the study, a patient must qualify in at least one anatomic or co-morbid
high-risk condition, as shown below:

Anatomic High Risk Conditions:

1. Patient has a target lesion at or above the second vertebral body (level of jaw) or
below the clavicle.

2. Patient has an inability to extend the head due to cervical arthritis or other
cervical disorders.

3. Patient is status/post radiation therapy to the neck.

4. Patient has a prior head and neck surgery in the region of the carotid artery.

5. Patient has spinal immobility of the neck.

6. Patient has the presence of tracheostomy stoma.

7. Patient has laryngeal palsy or laryngectomy.

8. Patient has a hostile neck or surgically inaccessible lesion.

9. Patient has severe tandem lesions.

Co-morbid High Risk Conditions:

1. Patient is ≥70 years of age (maximum 80 years) at the time of enrollment.

2. Patient has NYHA Class III or IV congestive heart failure (CHF) with LVEF <35%.

3. Patient has chronic obstructive pulmonary disease (COPD) with FEV <30%.

4. Patient has unstable angina.

5. Patient has had a recent myocardial infarction (≥30 days prior to stenting procedure).

6. Patient has coronary artery disease with two or more vessels with ≥ 70% stenosis.

7. Patient has planned CABG or valve replacement surgery between 31‐60 days after the CAS
procedure.

8. Patient requires peripheral vascular surgery or abdominal aortic aneurysm repair
between 31‐60 days following the CAS procedure.

9. Patient has contralateral laryngeal nerve paralysis

10. Patient has restenosis after a previous CEA.

11. Patient has contralateral occlusion in the ICA as the only comorbid high risk
condition.

Exclusion Criteria:

1. Patient has life expectancy of less than one year.

2. Patient is experiencing (or has experienced) an evolving, acute, or recent disabling
stroke in the last 30 days.

3. Patient has anticipated or potential sources of emboli (e.g. known previously
symptomatic patent foramen ovale (PFO), mechanical heart valve, or deep vein
thrombosis (DVT) treated within 6 months) that are not adequately treated with
antithrombotics for at least two weeks with documented coagulation parameters in the
target therapeutic range.

4. Patient has atrial fibrillation.

5. Patient has had an acute myocardial infarction within 60 days prior to index
procedure.

6. Patient has had or plans to have any major surgical procedure (i.e. intraabdominal or
intrathoracic surgery or any surgery/interventional procedure involving cardiac or
vascular system) within 30 days of the index procedure.

7. Patient has a history of major ipsilateral stroke.

8. Patient has >60% carotid stenosis contralateral to the target lesion requiring
treatment prior to completion of thes study-required 12 month follow-up.

9. Patient has a modified Rankin Scale of >2 or has another neurological deficit not due
to stroke that may confound the neurological patient assessments.

10. Patient has chronic renal insufficiency (serum creatinine ≥2.5 mg/dL) or has a history
of severe hepatic impairment, malignant hypertension, and/or is morbidly obese.

11. Patient has platelet count <100,000/μL.

12. Patient has known sensitivity to heparin or previous incidence of Heparin‐Induced
Thrombocytopenia (HIT) type II.

13. Patient has contraindication to standard of care study medications, including
antiplatelet therapy.

14. Patient has known sensitivity to contrast media that cannot be adequately controlled
with premedication.

15. Patient has known bleeding diathesis or hypercoagulable state or refuses blood
transfusions.

16. Patient has intracranial pathology that, in the opinion of the investigator, makes the
patient inappropriate for study participation (e.g. brain tumor, AVM, cerebral
aneurysm, cerebral vascular disease [microangiopathy or large vessel], etc.) or would
confound neurological evaluation.

17. Patient had intracranial hemorrhage within the last 90 days.

18. Patient is currently enrolled in another investigational study protocol and has not
completed its primary endpoint or that will confound the current study endpoints.
Patients who are involved in the long‐term surveillance of a clinical study are
eligible.

19. Patient suffers from confusion or dementia or is unable or unwilling to cooperate with
the study requirements and/or follow‐up procedures.

20. Patient has a known, unresolved history of drug use or alcohol dependency.

21. Patient has an active infection.

22. Patient has renal failure and/or is on dialysis.

23. Patient has documented uncontrolled diabetes.

24. Patient is pregnant.

Angiographic Exclusion Criteria

A patient is not eligible for enrollment in the study if he/she meets any of the following
angiographic exclusion criteria:

1. Patient has a total occlusion of the target carotid arteries (i.e., CCA or ICA).

2. Patient has a previously placed stent in the ipsilateral carotid artery.

3. Patient has severe lesion calcification or vascular tortuosity that may preclude the
safe introduction of the sheath, guiding catheter, embolic protection system, or
stent.

4. Patient has the presence of mobile filling defect or thrombus in target vessel.

5. Patient has occlusion or presence of "string sign" of the target vessel.

6. Patient has carotid (intracranial) stenosis located distal to target stenosis that is
more severe than target stenosis.

7. Patient has known mobile plaque or thrombus in the aortic arch.

8. Patient has a type III aortic arch.

9. Patient in whom femoral access is not possible.

10. Patient has intracranial arteriovenous malformations of the territory of the target
carotid artery.

11. Patient has an aneurysm in the territory of the target carotid artery that requires
treatment within 12 months.

12. Patient's ipsilateral carotid artery has 2 or more 90 degree bends in the target
landing zone.
We found this trial at
34
sites
Kingsport, Tennessee 37660
Principal Investigator: Chris Metzger, MD
Phone: 423-230-5642
?
mi
from
Kingsport, TN
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Michael Silva, MD
Phone: 409-772-5662
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
Korman Research Pavilion%2c Suite 100
Philadelphia, Pennsylvania 19141
215-456-7215
Principal Investigator: Jon George, MD
Phone: 215-456-1959
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
47 New Scotland Ave
Albany, New York 12208
(518) 262-3125
Principal Investigator: Alan Boulos, MD
Phone: 518-262-5938
Albany Medical College Albany Medical Center is northeastern New York's only academic health sciences center...
?
mi
from
Albany, NY
Click here to add this to my saved trials
Buffalo, New York 14215
Principal Investigator: Elad Levy, MD
Phone: 716-218-1000
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
503 North 21st Street
Camp Hill, Pennsylvania 17011
Phone: 717-724-6302
?
mi
from
Camp Hill, PA
Click here to add this to my saved trials
10700 East Geddes Avenue
Denver, Colorado 80112
Principal Investigator: Richard Bellon, MD
Phone: 720-493-3403
?
mi
from
Denver, CO
Click here to add this to my saved trials
3288 Moanalua Road
Honolulu, Hawaii 96816
Principal Investigator: Peter Schneider, MD
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
800 Prudential Drive
Jacksonville, Florida 32207
Principal Investigator: Ricardo Hanel, MD
Phone: 904-398-0125
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37934
Principal Investigator: Malcolm Foster, MD
Phone: 865-218-7535
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lebanon, New Hampshire
Principal Investigator: Rick Powell, MD
Phone: 603-650-7966
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Lexington, Kentucky 40503
Principal Investigator: Christian Ramsey, MD
Phone: 859-260-6344
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lincoln, Nebraska 68506
Principal Investigator: Robert Hibbard, MD
Phone: 402-483-3294
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Los Angeles, California 90027
Principal Investigator: Lei T. Feng, MD
Phone: 323-246-2751
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2301 South 3rd Street
Louisville, Kentucky 40241
Principal Investigator: Rob James, MD
Phone: 502-852-5251
?
mi
from
Louisville, KY
Click here to add this to my saved trials
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: Charles Matouk, MD
Phone: 203-737-7166
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Anthony Pucillo, MD
Phone: 212-342-3480
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10075
Principal Investigator: Mitchell Weinberg, MD
Phone: 212-434-3878
?
mi
from
New York, NY
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Principal Investigator: Johanna Fifi, MD
Phone: 212-241-2524
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Venkatesh Ramaiah, MD
Phone: 602-604-5021
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phoenix, Arizona
Principal Investigator: Rick Heuser, MD
Phone: 602-251-8890
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Raleigh, North Carolina 27607
Principal Investigator: Ravish Sachar, MD
Phone: 919-787-5380
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
4150 5th Street
Rapid City, South Dakota 57701
Principal Investigator: Joseph Tuma, MD
Phone: 605-755-3764
?
mi
from
Rapid City, SD
Click here to add this to my saved trials
2800 L Street
Sacramento, California 95816
Principal Investigator: Lofti Hacein-Bey, MD
Phone: 916-454-6973
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
3350 La Jolla Village Drive
San Diego, California 92161
Principal Investigator: John Lane, MD
Phone: 858-552-4352
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Sioux Falls, South Dakota 57108
Principal Investigator: J. Michael Bacharach, MD
Phone: 605-977-5336
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Springfield, Illinois 62701
Principal Investigator: Jeffrey Goldstein, MD
Phone: 217-492-9100
?
mi
from
Springfield, IL
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Principal Investigator: David Fiorella, MD
Phone: 631-444-1610
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Summit, New Jersey 07901
Principal Investigator: Mark Kumar, MD
Phone: 908-522-6279
?
mi
from
Summit, NJ
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Brian Kott, MD
Phone: 253-403-7258
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Washington, District of Columbia
Principal Investigator: Nelson Bernardo, MD
Phone: 202-277-8475
?
mi
from
Washington,
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
Principal Investigator: Don Heck, MD
Phone: 336-718-5871
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Wynnewood, Pennsylvania 19096
Principal Investigator: William Gray, MD
Phone: 484-476-8579
?
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Wyomissing, Pennsylvania 19610
Principal Investigator: Guy Piegari, MD
Phone: 610-685-4843
?
mi
from
Wyomissing, PA
Click here to add this to my saved trials